维立志博-B(09887)：LBL-024于奥帕替苏米单抗黑色素瘤Ib/Ⅱ期试验的首例患者成功用药
LEADS BIOLABS-BLEADS BIOLABS-B(HK:09887) 智通财经网·2025-09-12 04:29

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) highlights the initiation of a Phase Ib/II clinical trial for the drug Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) in treating advanced melanoma, marking a significant step in cancer therapy development [1] Group 1 - The Phase Ib/II multi-center clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals across the country [1] - The trial aims to evaluate the efficacy and safety of Opalizumab as a monotherapy or in combination with other agents for the treatment of advanced melanoma [1]